News
-
-
-
-
PRESS RELEASE
Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports
Lonza publishes invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports. Re-election and election of Board members, proposed dividend of CHF 4.00 per share maintained -
-
PRESS RELEASE
“Tunnel Ostbahnhof” joint venture awarded contract for eastern section of the Second Core S-Bahn Route in Munich
Implenia AG's joint venture awarded major contract for 'Tunnel Ostbahnhof' project as part of the Second Core S-Bahn Route in Munich, worth hundreds of millions of euros. Construction begins in June 2025 and aims for completion by May 2033 -
-
-
PRESS RELEASE
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares, l'anémie hémolytique à anticorps chauds et la maladie associée aux IgG4, sans traitement approuvé actuellement -
PRESS RELEASE
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for warm autoimmune hemolytic anemia and IgG4-related disease, potential use in immune thrombocytopenia. Sanofi's novel BTK inhibitor holds promise for rare diseases
